Sign In
Buy RGEN
$149.78
+2.72 (+1.85%)
At Close: Aug 04, 2026
Repligen Corporation's (RGEN) CEO Tony Hunt on Q4 2020 Results - Earnings Call Transcript
12:39pm, Wednesday, 24'th Feb 2021
Repligen Corporation's (RGEN) CEO Tony Hunt on Q4 2020 Results - Earnings Call Transcript
Repligen's (RGEN) Q4 Earnings and Revenues Surpass Estimates
10:38am, Wednesday, 24'th Feb 2021
Repligen (RGEN) beat estimates for both earnings and revenues in the fourth quarter of 2020.
Repligen: Q4 Earnings Insights
07:47am, Wednesday, 24'th Feb 2021
Shares of Repligen (NASDAQ:RGEN) remained unaffected after the company reported Q4 results. Quarterly Results Earnings per share increased 160.00% year over year to $0.52, which beat the estimate of $
Repligen Reports Fourth Quarter and Full Year 2020 Financial Results
07:30am, Wednesday, 24'th Feb 2021
WALTHAM, Mass., Feb. 24, 2021 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today reported financial results for its f
Repligen Corporation to Present at 10th Annual SVB Leerink Healthcare Conference
07:30am, Monday, 22'nd Feb 2021
WALTHAM, Mass., Feb. 22, 2021 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will present virtu
Repligen (RGEN) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
01:40pm, Wednesday, 17'th Feb 2021
Repligen (RGEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Repligen to Report Fourth Quarter and Full Year 2020 Financial Results
03:00pm, Thursday, 11'th Feb 2021
Webcast and Conference Call to Be Held Wednesday, February 24, 2021 at 8:30 a.m. EST WALTHAM, Mass., Feb. 11, 2021 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) today announced that the Compa
Repligen (RGEN) to Report Q4 Earnings: What's in the Cards?
12:06pm, Thursday, 11'th Feb 2021
On Repligen's (RGEN) fourth-quarter earnings call, investor focus will be on sales performance of its product franchisees - filtration, chromatography, protein and process analytics.
Repligen and Navigo Proteins Announce the Launch of an Affinity Resin for the Purification of COVID-19 Vaccines
07:36am, Monday, 08'th Feb 2021
WALTHAM, Mass. and HALLE (Saale), Germany, Feb. 08, 2021 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, and Navigo Prot
Repligen (RGEN) Outpaces Stock Market Gains: What You Should Know
06:56pm, Friday, 05'th Feb 2021
Repligen (RGEN) closed the most recent trading day at $222.06, moving +1.9% from the previous trading session.
Repligen Stock Doubled In 2020 — Why Covid Demand Is Fueling It
12:33pm, Thursday, 04'th Feb 2021
When it comes to coronavirus vaccines, think of Repligen as the man behind the curtain and RGEN stock as a tools powerhouse. Shares broke out of a cup base in January and hover in a buy zone.
Stock Market Analysis: Nasdaq Pullback Healthy; SolarEdge, Yatsen IPO Dive, Repligen In Buy Zone
04:06pm, Friday, 15'th Jan 2021
Stock market analysis: Nasdaq pullback healthy; SolarEdge, Yatsen IPO dive, Repligen in buy zone. Investor's Business Daily has been helping people invest smarter results by providing exclusive stock
Here's Why You Should Really Own Repligen in 2021
05:30pm, Wednesday, 13'th Jan 2021
The tailwinds behind the company's gains aren't going anywhere.
Repligen Corporation to Present at 39th Annual J.P. Morgan Healthcare Conference
01:00pm, Monday, 04'th Jan 2021
WALTHAM, Mass., Jan. 04, 2021 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will present virtu
Why Repligen Stock Soared 107% in 2020
10:01am, Friday, 01'st Jan 2021
The bioprocessing technology company gained momentum during the coronavirus pandemic.
